CHICAGO — Asciminib continued to confer superior efficacy and better safety and tolerability than bosutinib among patients with chronic-phase chronic myeloid leukemia, according to study results presented during ASCO Annual Meeting.
Researchers observed durable responses after 2 years of follow-up, with more patients assigned asciminib (ABL001, Novartis) experiencing major molecular response.
“Asciminib is a novel tyrosine kinase inhibitor [TKI] that specifically targets the ABL myristoyl pocket, which is a new site of binding. Other TKIs that we have had up until now are